Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human (FIH), Open-Label, Phase 1 Study of ADG206, a CD137 Agonist Antibody, in Subjects With Advanced/Metastatic Solid Tumors

NCT05614258 is registered in ClinicalTrials.gov with Adagene Inc as lead sponsor.

NCT NCT05614258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05614258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human (FIH), Open-Label, Phase 1 Study of ADG206, a CD137 Agonist Antibody, in Subjects With Advanced/Metastatic Solid Tumors
Lead sponsor
Adagene Inc
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 13, 2023
Completion date
August 30, 2026
Enrollment
14 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/metastatic solid tumors